"As Ajinomoto Bio-Pharma Services, we are able to provide our customers with a wider range of CDMO offerings across multiple production platforms," said David Enloe, President and CEO of Ajinomoto Bio-Pharma Services. "We have seen an ongoing shift in the bio-pharma space toward simplifying supply chains and consolidating CDMO networks. In response to that shift, we can now engage in deeper, trusted relationships with our customers fulfilling more of their supply chain demands."
"Unifying these individual Ajinomoto companies furthers our commitment to enhancing our trusted capabilities, quality services and responsiveness to our customers' needs," said Peter Stuyck, Sr. VP and Head of Operations, Europe for Ajinomoto Bio-Pharma Services. "Together, as a fully integrated and global CDMO, we can more successfully contribute to the health of patients worldwide."
Chemical Market has been in the industry since almost 40 years. We owe our success to you and since the last few years things have been crazy for the world at large. The editorial independence has never been more important.
Our articles and press releases come from reliable sources and we keep delivering high impact trustworthy news, reviews and technical articles and reports free from commercial or political influence.
We believe everyone deserves equal access to accurate news and there are many news aggregator sites but we don't participate in those as they have a very broad criteria where not all news articles sites can participate and not all of them are true articles written for the purpose of knowledge but mostly are commercialized. We bring you news and information in the chemical industry and provide vital information to make decisions based on fact and not fiction.
Subscribe our magazine for as little as Rs.50 a month (Rs. 600/yr) or $1 a month ($11.99/yr)
